European CHMP recommends approval of selpercatinib (Retsevmo) for treatment of RET-fusion positive non-small cell lung cancer, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer

Selpercatinib is a RET receptor tyrosine kinase inhibitor, inhibiting wild-type RET receptor tyrosine kinase and multiple mutated isoforms. Reported benefits include objective response rate and response duration in previously treated patients with above cancers.

Source:

European Medicines Agency